UNSPSC 51241100: Ophthalmic agents

This classification denotes drugs or other preparations that treat ocular disorders or disorders of the eyes.

UNSPSC 51241100 Ophthalmic agents is a Class code that, based on recent state and local activity, encompasses generic and branded pharmaceutical products supplied through cooperative purchasing agreements to state and local government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products—a solicitation that demonstrates the code's scope in practice spans a broader pharmaceutical supply pipeline than ophthalmic products alone. State and local issuers use cooperative purchasing vehicles to aggregate demand across multiple jurisdictions and facilities, leveraging vendor competition on price competitiveness (weighted at 75 percent in MMCAP's evaluation criteria), fixed pricing, electronic data interchange capability, and compliance with FDA requirements, cGMP standards, and Drug Supply Chain Security Act certification. Participating vendors must maintain relationships with authorized wholesalers, demonstrate pricing flexibility through flat-price or net-price formats, carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence, and accept a 3 percent administrative fee on contract purchases.

The geographic scope of recent activity centers on Minnesota and the MMCAP member states, including Oregon. MMCAP's cooperative purchasing model, administered by a state procurement office, signals that the code attracts multistate and regional issuers rather than individual jurisdictions. The single identifiable recent opportunity—MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026—reflects a competitive landscape where vendors must submit detailed product information including National Drug Codes, SKUs, UPCs, and manufacturing locations; maintain two-of-three authorized wholesaler relationships with chargeback systems in place; and comply with performance penalties of $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions, and awards take effect July 1, 2026, after products are confirmed available in the marketplace by May 15, 2026.